Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan

Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Shoko Deguchi, Toru Yamashita, Yoshio Ikeda, Tohru Matsuura, Hisashi Narai, Nobuhiko Omori, Yasuhiro Manabe, Taijyun Yunoki, Yoshiki Takao, Sanami Kawata, Kenichi Kashihara, Koji Abe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007, and a later group, comprising 69 patients treated between January 2008 and December 2009. The mean time from arrival at the hospital to the initiation of treatment was significantly reduced in the later group, from 82.6 minutes to 70.9 minutes. Intracerebral hemorrhage (ICH) occurred in 26 patients (22.8%); compared with patients without ICH, these patients had a significantly higher prevalence of cardiogenic embolism (88.5% vs 58.0%); greater warfarin use (26.8% vs 6.8%); higher mean National Institutes of Health Stroke Scale (NIHSS) scores on admission (16 vs 10), at 3 days after admission (14 vs 5), and at 7 days after admission (13.5 vs 3); and a lower Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score (7.8 vs 9.1). Patients who received edaravone had a higher prevalence of cardiogenic embolism (70.9% vs 36.4%), a higher recanalization rate (77.7% vs 36.4%), and lower NIHSS scores on admission and at 3 and 7 days after admission compared with those who did not receive edaravone. Our data suggest that administration of intravenous alteplase 0.6 mg/kg within 3 hours of stroke onset is safe and effective, that the NIHSS and Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score are useful predictors of ICH after tPA administration, and that warfarin-treated patients are more likely to develop symptomatic ICH despite an International Normalized Ratio

Original languageEnglish
Pages (from-to)190-196
Number of pages7
JournalJournal of Stroke and Cerebrovascular Diseases
Volume22
Issue number3
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Thrombolytic Therapy
Tissue Plasminogen Activator
Japan
Stroke
Cerebral Hemorrhage
National Institutes of Health (U.S.)
Alberta
Warfarin
Embolism
International Normalized Ratio
Intravenous Administration
Safety

Keywords

  • acute ischemic stroke
  • cardiogenic embolism
  • DWI-ASPECTS
  • edaravone
  • intracerebral hemorrhage
  • tPA
  • warfarin

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. / Kono, Syoichiro; Deguchi, Kentaro; Morimoto, Nobutoshi; Kurata, Tomoko; Deguchi, Shoko; Yamashita, Toru; Ikeda, Yoshio; Matsuura, Tohru; Narai, Hisashi; Omori, Nobuhiko; Manabe, Yasuhiro; Yunoki, Taijyun; Takao, Yoshiki; Kawata, Sanami; Kashihara, Kenichi; Abe, Koji.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 22, No. 3, 04.2013, p. 190-196.

Research output: Contribution to journalArticle

Kono, S, Deguchi, K, Morimoto, N, Kurata, T, Deguchi, S, Yamashita, T, Ikeda, Y, Matsuura, T, Narai, H, Omori, N, Manabe, Y, Yunoki, T, Takao, Y, Kawata, S, Kashihara, K & Abe, K 2013, 'Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan', Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 3, pp. 190-196. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.07.016
Kono, Syoichiro ; Deguchi, Kentaro ; Morimoto, Nobutoshi ; Kurata, Tomoko ; Deguchi, Shoko ; Yamashita, Toru ; Ikeda, Yoshio ; Matsuura, Tohru ; Narai, Hisashi ; Omori, Nobuhiko ; Manabe, Yasuhiro ; Yunoki, Taijyun ; Takao, Yoshiki ; Kawata, Sanami ; Kashihara, Kenichi ; Abe, Koji. / Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. In: Journal of Stroke and Cerebrovascular Diseases. 2013 ; Vol. 22, No. 3. pp. 190-196.
@article{096a179bb80047dc8d63dc8063a167ba,
title = "Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan",
abstract = "In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007, and a later group, comprising 69 patients treated between January 2008 and December 2009. The mean time from arrival at the hospital to the initiation of treatment was significantly reduced in the later group, from 82.6 minutes to 70.9 minutes. Intracerebral hemorrhage (ICH) occurred in 26 patients (22.8{\%}); compared with patients without ICH, these patients had a significantly higher prevalence of cardiogenic embolism (88.5{\%} vs 58.0{\%}); greater warfarin use (26.8{\%} vs 6.8{\%}); higher mean National Institutes of Health Stroke Scale (NIHSS) scores on admission (16 vs 10), at 3 days after admission (14 vs 5), and at 7 days after admission (13.5 vs 3); and a lower Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score (7.8 vs 9.1). Patients who received edaravone had a higher prevalence of cardiogenic embolism (70.9{\%} vs 36.4{\%}), a higher recanalization rate (77.7{\%} vs 36.4{\%}), and lower NIHSS scores on admission and at 3 and 7 days after admission compared with those who did not receive edaravone. Our data suggest that administration of intravenous alteplase 0.6 mg/kg within 3 hours of stroke onset is safe and effective, that the NIHSS and Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score are useful predictors of ICH after tPA administration, and that warfarin-treated patients are more likely to develop symptomatic ICH despite an International Normalized Ratio",
keywords = "acute ischemic stroke, cardiogenic embolism, DWI-ASPECTS, edaravone, intracerebral hemorrhage, tPA, warfarin",
author = "Syoichiro Kono and Kentaro Deguchi and Nobutoshi Morimoto and Tomoko Kurata and Shoko Deguchi and Toru Yamashita and Yoshio Ikeda and Tohru Matsuura and Hisashi Narai and Nobuhiko Omori and Yasuhiro Manabe and Taijyun Yunoki and Yoshiki Takao and Sanami Kawata and Kenichi Kashihara and Koji Abe",
year = "2013",
month = "4",
doi = "10.1016/j.jstrokecerebrovasdis.2011.07.016",
language = "English",
volume = "22",
pages = "190--196",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan

AU - Kono, Syoichiro

AU - Deguchi, Kentaro

AU - Morimoto, Nobutoshi

AU - Kurata, Tomoko

AU - Deguchi, Shoko

AU - Yamashita, Toru

AU - Ikeda, Yoshio

AU - Matsuura, Tohru

AU - Narai, Hisashi

AU - Omori, Nobuhiko

AU - Manabe, Yasuhiro

AU - Yunoki, Taijyun

AU - Takao, Yoshiki

AU - Kawata, Sanami

AU - Kashihara, Kenichi

AU - Abe, Koji

PY - 2013/4

Y1 - 2013/4

N2 - In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007, and a later group, comprising 69 patients treated between January 2008 and December 2009. The mean time from arrival at the hospital to the initiation of treatment was significantly reduced in the later group, from 82.6 minutes to 70.9 minutes. Intracerebral hemorrhage (ICH) occurred in 26 patients (22.8%); compared with patients without ICH, these patients had a significantly higher prevalence of cardiogenic embolism (88.5% vs 58.0%); greater warfarin use (26.8% vs 6.8%); higher mean National Institutes of Health Stroke Scale (NIHSS) scores on admission (16 vs 10), at 3 days after admission (14 vs 5), and at 7 days after admission (13.5 vs 3); and a lower Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score (7.8 vs 9.1). Patients who received edaravone had a higher prevalence of cardiogenic embolism (70.9% vs 36.4%), a higher recanalization rate (77.7% vs 36.4%), and lower NIHSS scores on admission and at 3 and 7 days after admission compared with those who did not receive edaravone. Our data suggest that administration of intravenous alteplase 0.6 mg/kg within 3 hours of stroke onset is safe and effective, that the NIHSS and Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score are useful predictors of ICH after tPA administration, and that warfarin-treated patients are more likely to develop symptomatic ICH despite an International Normalized Ratio

AB - In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007, and a later group, comprising 69 patients treated between January 2008 and December 2009. The mean time from arrival at the hospital to the initiation of treatment was significantly reduced in the later group, from 82.6 minutes to 70.9 minutes. Intracerebral hemorrhage (ICH) occurred in 26 patients (22.8%); compared with patients without ICH, these patients had a significantly higher prevalence of cardiogenic embolism (88.5% vs 58.0%); greater warfarin use (26.8% vs 6.8%); higher mean National Institutes of Health Stroke Scale (NIHSS) scores on admission (16 vs 10), at 3 days after admission (14 vs 5), and at 7 days after admission (13.5 vs 3); and a lower Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score (7.8 vs 9.1). Patients who received edaravone had a higher prevalence of cardiogenic embolism (70.9% vs 36.4%), a higher recanalization rate (77.7% vs 36.4%), and lower NIHSS scores on admission and at 3 and 7 days after admission compared with those who did not receive edaravone. Our data suggest that administration of intravenous alteplase 0.6 mg/kg within 3 hours of stroke onset is safe and effective, that the NIHSS and Diffusion-Weighted Imaging-Alberta Stroke Program Early CT Score are useful predictors of ICH after tPA administration, and that warfarin-treated patients are more likely to develop symptomatic ICH despite an International Normalized Ratio

KW - acute ischemic stroke

KW - cardiogenic embolism

KW - DWI-ASPECTS

KW - edaravone

KW - intracerebral hemorrhage

KW - tPA

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84875150705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875150705&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2011.07.016

DO - 10.1016/j.jstrokecerebrovasdis.2011.07.016

M3 - Article

VL - 22

SP - 190

EP - 196

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 3

ER -